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OBJECTIVES To compare the hemodynamic effects of twice daily metoprolol tartrate (MT) and once daily
metoprolol succinate (MS) in congestive heart failure patients.
BACKGROUND Adverse hemodynamic effects with MT demonstrated during initiation persist with drug
readministration during chronic therapy.
METHODS Patients were randomly assigned to 6.25 mg MT or 25 mg MS orally and the dose was
gradually increased to a target of 50 mg twice a day or 100 mg once a day, respectively.
Hemodynamic measurements were obtained at baseline and after three months of therapy—
both before and after drug readministration.
RESULTS Long term metoprolol therapy produced significant functional, exercise and hemodynamic
benefits with no difference in response between either metoprolol preparation in the 27
patients (MT [14], MS [13]). When full dose metoprolol was readministered during chronic
therapy, there were parallel adverse hemodynamic effects in both drug groups. Cardiac index
decreased by 0.6 liters/min/m2 (p , 0.0001) with MT and by 0.5 liters/min/m2 (p , 0.0001)
with MS. Systematic vascular resistance increased by 253 dyne-sec-cm25 (p , 0.001) with
MT and by 267 dyne-sec-cm25 (p , 0.0005) with MS. Stroke volume index decreased by
7.0 ml/m2 (p , 0.0005) with MT and by 6.5 ml/m2 (p , 0.0001) with MS, while SWI
decreased by 6.2 g-m/m2 (p , 0.0005) with MT and by 6.0 g-m/m2 (p , 0.001) with MS.
CONCLUSION Metoprolol tartrate and MS produce similar hemodynamic and clinical effects acutely and
chronically despite the fourfold greater starting dose of MS used in this study. A more rapid
initiation with readily available starting doses of MS may offer distinct advantages compared
with MT in treating chronic heart failure patients with beta-adrenergic blocking agents. (J
Am Coll Cardiol 2000;35:45–50) © 1999 by the American College of Cardiology
Mortality benefits with both beta-1 selective and beta
nonselective adrenergic blockers in congestive heart failure
have now been shown in three recent survival trials (1–3).
However, despite these impressive mortality results, the use
of beta-adrenergic blocking agents to treat heart failure
requires careful medical management. Initiation of therapy
with low dose beta-blockers can cause adverse hemody-
namic effects by decreasing cardiac output and increasing
systemic vascular resistance. These adverse hemodynamic
effects generally do not cause significant clinical deteriora-
tion but may require dose adjustments of concomitant
medications. Gradual up-titration of any beta-blocker is
achieved over several weeks (with adjustments of diuretics
and angiotensin-converting enzyme inhibitors as clinically
indicated) to achieve eventual target doses.
We have previously shown that the acute adverse hemo-
dynamic effects with initial low dose metoprolol tartrate
(MT) therapy persist in patients with heart failure during
long term treatment when “full” target doses are readmin-
istered (4). Metoprolol succinate (MS), the drug that was
used in Metoprolol Randomized Intervention Trial
(MERIT-HF) (3), is a longer acting formulation of meto-
prolol that is dosed once daily (q.d.). We hypothesized that
the adverse hemodynamic effects seen with MT may have
been due to variations in peak and trough drug levels with a
twice a day (b.i.d.) dosed drug and that a longer acting
formulation would have less variation of drug levels and
consequently not demonstrate any hemodynamic compro-
mise with subsequent dosing.
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Therefore, the objective of this study was to compare the
acute and chronic hemodynamic response of MT with that
of MS in patients with chronic heart failure being initiated
on beta-blocker therapy. Additionally, we studied the safety
of a more rapid initiation and dose up-titration with MS
compared with the conventional dosing and up-titration of
MT.
METHODS
Patient population. Eligible patients had chronic heart
failure with symptoms of persistent dyspnea or fatigue at
rest or on exertion (New York Heart Association [NYHA]
class II to IV) despite intensive therapy with digoxin,
diuretics and a converting enzyme inhibitor. All patients
were enrolled while clinically stable without evidence of
peripheral edema, having not received IV diuretics for at
least two weeks before baseline evaluation. Patients were
excluded from the study if they had experienced an acute
myocardial infarction within six weeks, an acute exacerba-
tion of heart failure within two weeks, history of obstructive
lung disease, claudication, a systolic blood pressure less then
85 mm Hg or a resting heart rate less than 64 beats/min.
The study was approved by the institutional review board
and patients signed informed consent prior to enrollment
into the study.
Study design. Following this stabilization period, each
patient’s clinical status was assessed by a review of symptoms
and by determination of the NYHA functional class. Each
patient underwent a 6-min walk test to assess submaximal
exercise endurance (5) and bicycle ergometry with gas
exchange to assess peak maximal oxygen consumption (6).
A right heart catheterization was performed for measure-
ment of intracardiac pressures via an internal jugular ap-
proach using local anesthetic and fluoroscopic guidance with
a triple lumen flow directed thermodilution catheter.
The next morning baseline hemodynamic measurements
were determined in the fasting state (7). Complete details of
the hemodynamics protocol have been published previously
(4). In brief, three complete sets of hemodynamic measure-
ments [right atrial, pulmonary artery and pulmonary capil-
lary wedge pressures (PCW)] with four determinations of
thermodilution cardiac output with iced injectate were
obtained 5 to 10 min apart for baseline values. A baseline
left ventricular filling pressure of $14 mm Hg was required
for continuation in the study. All cardiac medications
(digoxin, diuretics and angiotensin converting enzyme in-
hibitor) were held either for 12 hours (for three times a day
or b.i.d. medications) or 24 h (for q.d. medications) before
the hemodynamic evaluations for that day except for the test
drug (metoprolol) as indicated. Blood was collected from
the indwelling catheter side port for the measurement of
plasma norepinephrine after the patients had rested in the
supine position for at least 30 min.
Patients were randomly assigned to receive open-label
MT or MS. The initial dose of MT was 6.25 mg and the
initial dose of MS was 25 mg. Hemodynamic measurements
were then repeated 2 hours after the initial dose of assigned
metoprolol. Patients were discharged home on their as-
signed medication: either MT 6.25 mg po b.i.d. (Lopressor:
Novartis, East Hanover, New Jersey; recompounded by
hospital research pharmacist for doses through 12.5 b.i.d.;
subsequent doses given via prescription) or 25 mg MS
(Toprol XL: Astra Zeneca, Wayne, Pennsylvania). Patients
were seen once a week for the subsequent 4 week period.
Metoprolol tartrate was increased to 12.5 po b.i.d., 25 mg
po b.i.d. and 50 mg po b.i.d. sequentially each week if the
prior dose was clinically tolerated. Metoprolol tartrate was
increased to 50 mg q.d. and then 100 mg q.d. each week.
The target dose of MT was 50 mg b.i.d. and MS was
100 mg q.d., but for patients weighing more than 85 kg, the
target was doubled. A fallback dose of 25 mg b.i.d. of MT
and 50 mg of MS was allowed based on patient response.
Thus, by protocol design the time to reach target dose with
MS was one half that of MT. If there were significant signs
or symptoms of bradycardia, orthostasis or worsening con-
gestive heart failure, the metoprolol dose was held constant
or reduced and reevaluated for increase the following visit.
Diuretics were adjusted when there was evidence of fluid
retention.
After three months of continuous therapy, all clinical and
exercise assessments were repeated. A repeat right heart
catheterization was performed for measurement of intracar-
diac pressures in an identical manner to the initial hemo-
dynamic evaluation. The following morning, long term
baseline hemodynamic measurements were determined in
the fasting state prior to the metoprolol dose (trough).
Blood was again collected from the indwelling catheter for
the measurement of plasma norepinephrine after the pa-
tients had rested in the supine position for at least 30 min.
After the next scheduled full dose of MT or MS was given,
hemodynamic variables were redetermined 2 h later. All
other cardiac medications were held until the completion of
hemodynamic readings for that day.
Statistical analysis. A two-way repeated measures analysis
of variance was used to assess the significance of the between
Abbreviations and Acronyms
b.i.d. 5 twice a day
CI 5 cardiac index
MERIT-HF 5 Metoprocol Randomized Intervention
Trial
MS 5 metoprolol succinate
MT 5 metoprolol tartrate
NYHA 5 New York Heart Association
PCW 5 pulmonary capillary wedge pressure
q.d. 5 every day
SVI 5 stroke volume index
SVR 5 systemic vascular resistance
SWI 5 stroke work index
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group differences of the completers for each hemodynamic
parameter with respect to changes from baseline to the
following three time points: 1) 2 h after the first dose, 2)
long term trough, and 3) long term peak. For clinical
responses, a paired t test was used with respect to changes
from baseline.
Following these overall tests, within group hemodynam-
ics were compared for MT and MS, respectively, using the
Student t test for paired data. Group data are expressed as
means 6 SD. All hemodynamic parameters measuring peak
effect of drug are reported as the readings from 2 h after the
drug was given (to avoid a bias in evaluating drug effect).
Two hours was chosen as a pharmacologic approximation of
full absorbance of MT. A p value of #0.05 was considered
significant.
RESULTS
Twenty-seven patients entered the study. Four patients
were NYHA class II, 19 were class III and 4 were class IV.
All patients had a left ventricular ejection fraction less than
25% as assessed by radionuclide ventriculography, ranging
from 6% to 18% with a mean of 11%. There were 24 men
and 3 women with a mean age of 50 (range 29 to 72). The
cause of heart failure was ischemic heart disease in 8
patients, primary cardiomyopathy in 18 patients and valvu-
lar cardiomyopathy in one. There were 15 whites, 6 blacks
and 6 hispanic patients, equally divided between drug
groups.
Of the 27 patients, 26 were on ACEI as background
therapy—captopril (9), enalapril (12) or lisinopril (5),
equally divided between MT and MS. Converting to
enalapril equivalence doses, both groups were taking an
average daily dose of 16 mg. Of the 27 patients, 26 were
taking furosemide and one was taking bumetanide. By
furosemide equivalents, the mean dose for the MT patients
was 133 mg and for the MS patients was 108 mg with no
between group difference. Additionally, six patients were
taking supplemental metolazone (four in the MT group,
two in the MS group). All patients were taking digoxin with
an equal mean dose of 0.22 mg.
Fourteen patients were randomly assigned to MT and 13
patients were randomly assigned to MS. The groups were
evenly matched at baseline following randomization (Table
1). Twenty-four patients (89%) completed the protocol and
the long term hemodynamic evaluation. One patient did not
tolerate low dose MT and withdrew from the study. One
patient died suddenly on MT 25 mg b.i.d. One MS patient
returned to his home in St. Lucia and did not complete the
repeat hemodynamic evaluation. Eleven completers reached
the target dose of MT 50 mg po b.i.d.; two patients (one of
whom died) received 25 mg po b.i.d. due to intolerance at
the higher dose. All 13 patients assigned to MS reached
target dose (11 patients at 100 mg and for two patients the
target was 200 mg based on weight).
Clinical response. Overall, long term therapy with meto-
prolol was associated with significant functional and exercise
improvements in those patients who completed the proto-
col. New York Heart Association class improved by one
functional class (chi-square p , 0.0001) with no between
group differences. Metoprolol tartrate patients who com-
pleted the study improved their NYHA class from 0/2/8/2
to 3/6/3/0, while MS patients who completed the study
improved from 0/1/10/1 to 0/9/3/0. Measurements of both
submaximal and maximal exercise capacity showed im-
provements. Distance on the 6 min walk increased from
1,117 6 299 to 1,237 6 367 feet with MT and from 927 6
221 to 1,212 6 301 feet with MS with no between group
difference. Similarly maximal oxygen consumption in-
creased from 12.8 6 3.5 to 14.9 6 4.9 ml/kg/min with MT
and from 11.3 6 3.7 to 14.4 6 4.5 ml/kg/min with no
between group difference.
Ejection fraction increased from 11.5% 6 3.6% to
17.0% 6 5.7% with MT and from 10.4% 6 2.8% to 14.1%
6 4.1% with MS, with no between group difference.






Gender (m/f) 11/3 13/0
Etiology (ischemic/idiopathic/valvular) 3/11/0 5/7/1
NYHA (II/III/IV) 2/9/3 2/10/1
Mean arterial pressure (mm Hg) 82 6 12.3 86 6 12.5
Heart rate (beats/min) 94 6 10.9 92 6 15.2
Mean pulmonary artery pressure (mm Hg) 41 6 6.3 41 6 9.4
Pulmonary capillary wedge pressure (mm Hg) 30 6 5.6 28 6 7.9
Right atrial pressure (mm Hg) 12 6 7.1 13 6 5.1
Cardiac index (L/min/m2) 2.1 6 0.4 2.4 6 0.57
Systemic vascular resistance dynes-s/cm5 1,348 6 334 1,280 6 454
Stroke volume index (mL/m2) 22.8 6 5.5 27.1 6 10.3
Stroke work index (g-m/m2) 16.2 6 5.5 20.9 6 8.1
Left ventricular ejection fraction (%) 11.9 6 3.3 10.5 6 2.6
Values are means 6 SD. There was no significant difference between any groups in any parameter.
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Measurements of norepinephrine levels showed parallel
declines: 539 6 172 to 455 6 295 pg/ml with MT and
607 6 223 to 484 6 233 pg/ml with MS, p 5 NS between
groups.
Hemodynamics. For all hemodynamic variables, there
were statistically significant time effects (p , 0.005) with no
overall separate drug effects (p . 0.2). There was no
interaction (p . 0.5) between groups. The changes within
drug groups was consistent over time for the two treatments.
The acute adverse hemodynamic effects of 6.25 mg MT
were similar to those seen with 25 mg of MS despite the
fourfold difference in dose. Cardiac index (CI) decreased by
0.2 l/min/m2 (p , 0.001) with MT and by 0.3 l/min/m2
(p , 0.01) with MS. Systemic vascular resistance (SVR)
increased by 176 dyn-sec-cm(25) (p , 0.0025) with MT
and by 128 dyn-sec-cm(25) (p , 0.05) with MS. Conse-
quently, stroke volume index (SVI) declined by 2.8 ml/m2
(p , 0.0025) with MT and by 3.0 ml/m2 (p , 0.025) with
MS. Furthermore, stroke work index (SWI) acutely de-
creased by 1.4 g-m/m2 (p , 0.025) with MT and by 2.7
g-m/m2 (p , 0.025) with MS.
Continuous therapy with metoprolol demonstrated sig-
nificant long term parallel hemodynamic benefits when
measured before the next scheduled dose of metoprolol
(trough) in addition to the clinical benefits described above.
For those completing the study, resting heart rate decreased
from 93 6 11.2 to 73 6 13.7 (p , 0.005) beats/min with
MT and a similar 93 6 15.8 to 73 6 16.9 (p , 0.001)
beats/min with MS. Pulmonary capillary wedge pressure
(PCW) decreased from 29.1 6 5.5 to 22.5 6 9.8 mm Hg
(p 5 NS) with MT and from 28.8 6 8.0 to 22.3 6
6.8 mm Hg (p , 0.05) with MS. Cardiac index increased
from 2.1 6 0.4 to 2.7 6 0.5 liters/min/m2 (p , 0.01) with
MT and from 2.4 6 0.6 to 2.7 6 0.6 liters/min/m2 (p 5
NS) with MS. Systematic vascular resistance decreased from
1,287 6 297 to 1,002 6 246 dyne-sec-cm25 (p , 0.05)
with MT and from 1,300 6 468 to 1,083 6 257 dyne-sec-
cm25 (p 5 NS) with MS. Importantly, SVI increased from
23.2 6 5.8 to 39.0 6 12.8 ml/m2 (p , 0.005) with MT and
from 27.0 6 10.8 to 37.9 6 9.6 ml/m2 (p , 0.0005) with
MS. Stroke work index increased from 16.3 6 5.8 to 30.5 6
13.7 g-m/m2 (p , 0.01) with MT and from 21.0 6 8.4 to
30.3 6 9.4 g-m/m2 (p , 0.0001) with MS.
In order to determine the subsequent hemodynamic
effects of full dose metoprolol after three months of contin-
uous therapy, measurements were compared between long
term baseline and 2 h after the next scheduled full dose of
metoprolol. The p values represent the differences between
long term baseline and long term peak within group. When
the next full dose of metoprolol was administered, CI
decreased by 0.6 liters/min/m2 (p , 0.0001) with MT and
by 0.5 liters/min/m2 (p , 0.0001) with MS. This occurred
while SVR increased by 253 dyne-sec-cm25 (p , 0.001)
with MT and by 267 dyne-sec-cm25 (p , 0.0005) with
MS. Furthermore, SVI decreased by 7.0 ml/m2 (p ,
0.0005) with MT and by 6.5 ml/m2 (p , 0.0001) with MS.
Finally, SWI decreased by 6.2 g-m/m2 (p , 0.0005) with
MT and by 6.0 g-m/m2 (p , 0.001) with MS.
The changes with PCW, SVR, SVI and SWI are shown
graphically for four time points (baseline, 2 h after first dose,
long term trough after three months of metoprolol therapy
and 2 hours after drug readministration) in Figure 1 for the
24 patients who completed the protocol.
DISCUSSION
Despite the known adverse acute hemodynamic effects of
beta-blockade, there is compelling evidence that chronic
beta-blockade provides long term hemodynamic, symptom-
atic, exercise (8–16) and survival benefits (1–3) in patients
with congestive heart failure. Due to the negative hemody-
namic effects of beta-blockers in heart failure, therapy is
initiated with minute doses of beta-blockers and only
gradually increased over the course of several weeks.
In this study, patients treated with the shorter acting MT
or the longer acting MS exhibited significant parallel long
term hemodynamic improvements before the next dose of
drug (trough period) following a minimum of 3 months of
therapy. As was seen with MT previously (4), each subse-
quent full dose of either metoprolol preparation, upon
readministration, produced significant similar declines in
CI, SVI and SWI, with an increase in SVR.
A probable mechanism of this phenomenon of adverse
hemodynamics with beta-blockers is a disruption of the
delicate balance between the negative hemodynamic (pre-
sumably as a negative inotrope) properties of metoprolol due
to adrenergic withdrawal and the beneficial effects of block-
ing norepinephrine (thereby chronically improving left ven-
tricular function). Even after three months of continuous
metoprolol therapy, the negative hemodynamic effects are
still measurable with the next dose (peak), albeit with an
overall net of hemodynamic and clinical benefit of chronic
metoprolol therapy.
The persistent adverse hemodynamic effects of MT did not
differ when compared with the longer acting MS. Although we
do not have drug levels to correlate with hemodynamics, the
adverse hemodynamics are temporally related to drug readmin-
istration. It is important to note that the chronic adverse
hemodynamic effects with subsequent dosing are not associated
with any clinical deterioration. In fact, over the long term,
patients demonstrate substantial clinical and hemodynamic
benefits. Of perhaps even greater significance, in this study, we
were able to demonstrate the safety of a more rapid initiation
with a dose of 25 mg and a subsequent uptitration of MS over
a two to three week period compared with the conventional
initiation of the cumbersome 6.25 mg MT (which requires
recompounding) and gradual uptitration of MT over a four to
six week time frame. This schedule of MS would allow for a
faster initiation and easier uptitration of metoprolol in clinical
practice if safety is demonstrated in a larger trial. The MS
dosing utilized here was more rapid than that used in
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MERIT-HF (3). We increased the dosing weekly, and our
target was 100 mg q.d. rather than the dosing schedule in
MERIT of doubling every other week to a target of 200 mg
q.d. Additionally, all of our patients started at 25 mg q.d.,
whereas in MERIT, only NYHA II patients started at 25 mg;
NYHA III patients were started at 12.5 mg.
Study limitations. We did not measure inotropy of the
ventricle; our results are based on hemodynamic indexes
that reflect loading conditions as well as contractility. This
is an open label study. This may bias the subjective clinical
results to show overall improvement but probably does not
affect the more objective hemodynamic results.
Conclusions. This study reconfirms the beneficial hemo-
dynamic, clinical and exercise benefits of beta-blocker ther-
apy in a moderate to severely symptomatic heart failure
population. Parallel results were seen with MT and MS.
Most importantly, we have demonstrated that initiation of
therapy with MS can be achieved more rapidly yet with the
same safety profile as that with MT. Ease of administration
may allow for wider use of beta-blocker therapy in clinical
practice which is essential given the newly demonstrated
mortality benefits and the recently revised heart failure
clinical guidelines promulgating beta-blocker use in heart
failure (17).
Figure 1. Hemodynamic indexes of a) pulmonary capillary wedge pressure, b) stroke volume index, c) systemic vascular resistance, and d)
stroke work index at baseline (B), peak–2 h after initial drug administration (P), long term trough after 3 months of metoprolol therapy
(LT-b) and 2 h after drug readministration (LT-p). Error bars are SEM. P values are designated to show differences from B to 2 h, B
to LT-B and from LT-B to LT-P within groups. Symbols under the lines refer to MT and symbols above the lines refer to MS. There
were no between group differences for any changes. MS 5 metoprolol succinate; MT 5 metoprolol tartrate. *p , 0.001, †p , 0.01, §p ,
0.05.
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